EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review

Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu iD, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03063-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Patrick Eugeni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists, Antibodies, Monoclonal, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for the treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, and migraine-related healthcare resource utilization (HCRU) after the addition of fremanezumab for preventive migraine treatment in patients using gepants for acute treatment. METHODS: Data were extracted during a retrospective chart review from electronic medical records from the Dent Neurologic Institute. Eligible patients were ≥ 18 years old, using gepants (rimegepant or ubrogepant), who initiated fremanezumab between January 1, 2020, and May 1, 2021 (index date: date of fremanezumab initiation) and continued concomitant use of gepants and fremanezumab for ≥ 1 month (post-index; between 7-9 months of follow-up). Outcomes included monthly migraine days (MMD), adverse events (AEs), reasons for discontinuation, and migraine-related HCRU. RESULTS: A total of 55 patients [female, 93%; mean (SD) age, 43.5 (13.5) years] met the inclusion criteria. All patients were diagnosed with chronic migraine. Patients had an average (SD) MMD of 15.8 (7.4) at the index date. Average (SE) change in MMD from index date to post-index was - 6.5 (1.0) days (p < 0.0001). Five patients (9.1%) experienced AEs post-index; no serious AEs (SAEs) were reported. The number of migraine-related medications used decreased from the index date to post-index by a mean of 0.6 for preventive medications (p = 0.070), and 0.8 for acute medications (p = 0.050). The number of outpatient office-based visits also decreased [mean (SD): 6 months pre-index, 5.8 (4.4) vs. 6 months post-index, 4.1 (4.0); p < 0.0001]. CONCLUSION: The addition of fremanezumab preventively to gepants for acute migraine treatment was effective, resulted in fewer outpatient office visits, and yielded no SAEs or AEs that were novel to these migraine medication classes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, MonoclonalPyrrolesPyridinesPatient Acceptance of Health CareHumansRetrospective StudiesMaleFemaleMiddle AgedAdultUnited StatesDrug Therapy, CombinationTreatment OutcomePiperidines

Stichwörter der Autor:innen

CGRPFremanezumabGepantsHCRUMigraineReal-world evidence

Substanzen

fremanezumabCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, MonoclonalubrogepantPyrrolesrimegepant sulfatePyridinesPiperidines

Autor:innen und Institutionen

  • Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA.
  • Teva Pharmaceuticals, Amsterdam, Netherlands.
  • Teva Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
  • Teva Pharmaceuticals, Parsippany, NJ, USA.
  • Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA. jmcvige@DENTINSTITUTE.COM.

ORCID-Profile: Zhongzheng Niu

Förderung

  • Teva Pharmaceuticals

Zitieren

APA

Eugeni, P., Rooney, M. E., Saikali, N. P., Niu, Z., Driessen, M. T., Krasenbaum, L. J., Carr, K., Seminerio, M. J., & McVige, J. W. (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in Therapy. https://doi.org/10.1007/s12325-024-03063-w

Vancouver

Eugeni P, Rooney ME, Saikali NP, Niu Z, Driessen MT, Krasenbaum LJ, et al. US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in Therapy. 2025. doi:10.1007/s12325-024-03063-w

BibTeX
@article{Eugeni2025,
  author = {Eugeni, Patrick and Rooney, Megan E and Saikali, Nicolas P and Niu, Zhongzheng and Driessen, Maurice T and Krasenbaum, Lynda J and Carr, Karen and Seminerio, Michael J and McVige, Jennifer W},
  title = {US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03063-w}
}
Kostenlos starten →